



February 2024

Dear Valued Customer,

As your trusted partner in influenza vaccination efforts and public health, Sanofi is sharing this important update for the upcoming 2024-25 influenza season.

Based upon a declining global trend of circulating B/Yamagata flu strain prior to the COVID-19 pandemic, the Food and Drug Administration (FDA), in alignment with the recommendation of the World Health Organization (WHO), has stated its preference for vaccine manufacturers to remove B/Yamagata from all influenza vaccines in the US by the 2024-2025 season¹⁻². As the likelihood of this transition from Quadrivalent (QIV) to Trivalent (TIV) influenza vaccine formulations is high, Sanofi is working actively with the FDA to support this effort. The Vaccines and Related Biologic Products Advisory Committee (VRBPAC) will meet again in March 2024 to vote on the final 2024-25 Northern Hemisphere (NH) Influenza vaccine composition.

- **Sanofi is working to transition our influenza vaccines to the TIV formulation while maintaining the highest quality production standards.** We are working to ensure supply of quality influenza vaccines for the US market, delivered to meet commitments. We are also prepared to provide whatever the FDA licenses, QIV or TIV.
- **Please note that in some parts of the world, both QIV and TIV formulations will be available, given the more immediate timing of the next influenza season.**
- **The 2024 contracting and prebook process will continue as normal.** Contracts, if not updated prior to issuing, will be updated via Notification of Amendment (will not require customer signature) to reflect TIV and associated NDC codes. Should the FDA license QIV influenza vaccines for any presentation, Sanofi is prepared to revert to QIV and will provide associated NDC codes via a Notification of Amendment for the '24/25 season. CPT codes will be available to support TIV presentations or QIV if necessary.

Thank you for your essential role in preventing influenza through immunization. We recognize that you are one of the most trusted sources of information for patients. We strive to keep you informed so we can partner to educate and immunize your patients to prevent influenza disease and its complications.

Thank you,

Dominika Kovacs

Head of US Adult Business Unit, Sanofi Vaccines